Our passion, your health.

QUELLENANGABEN


    1. Hoppe HD, Lobmann R: Medizin & Praxis 2008; Spezial Mai, Chronische Wunden: 77–82

    2. Fleischmajer, R “Human dermal glycosaminglycans and aging, 1972

    3. Meyer LJ, Stern R “Age-dependent changes of hyaluronan in human skin“, J Invest Dermatol. 1994 Mar; 102(3):385-9

    4. Dowsett, C, Newton H “Wound bed preparation: TIME in practice” WOUNDS UK, 2005, 1. Jg., Nr. 3, S. 58

    5. Lokaltherapie chronischer Wunden bei Patienten mit den Risiken periphere arterielle Verschlusskrankheit, Diabetes mellitus, chronisch venöse Insuffizienz; Registernummer 091 – 001; Stand: 12.06.2012, gültig bis 30.04.2016

    6. Onesti MG, Fioramonti P, Fino P, Sorvillo V, Carella S, Scuderi N. “Effect of enzymatic debridement with two different collagenases versus mechanical debridement on chronic hard-to-heal wounds.” Int Wound J 2015; doi: 10.1111/iwj.12421

    7. Onesti MG et al.: Eur Rev Med Pharmacol Sci. 2013; 17(2): 210–6

    8. Onesti MG, Fino P, Ponzo I, Ruggieri M, Scuderi N. “Non-surgical treatment
      of deep wounds triggered by harmful physical and chemical agents: a successful combined use of collagenase and hyaluronic acid” 2014

    9. Karousou E. et al.: Eur Journal of Acne and Relate Diseases 2015; 6

    10. Gravante G et al.: Eur Rev Med Pharmacol Sci 2013; 17(20): 2721–7

    11. Schlesinger T, Powell CR.: J Clin Aesthet Dermatol 2012; 5(10): 20–23

    12. Ortonne JP: Journal of Dermatological Treatment 1996; 0954-6634

    13. Wright, JB “Efficacy of topical silver against fungal burn wound pathogens” 1999

    14. Lansdown, ABG “A Pharmacological and Toxicological Profile of Silver as an Antimicrobial Agent in Medical Devices” 2010

    15. Costagliola M, Agrosi M. Second-degree burns: a comparative, multicenter, randomized trial of hyaluronic acid plus silver sulfadiazine vs. silver sulfadiazine alone. Curr Med Res Opin 2005; 21:1235–1240

    16. Koller J. Topical treatment of partial thickness burns by silver sulfadiazine plus hyaluronic acid compared to silver sulfadiazine alone: a double blind, clinical study. Drugs Exp Clin Res
      2004; 30:183–190

    17. Zanetti E. & Calosso A. [Prevenzione e trattamento delle Lesioni da Decubito]. Lauri Ed. Milano, 2000

    18. Peghetti A, Bellingeri A, Pomponio G, Sansoni J, Paladino D. Efficacia dell’acido ialuronico associate alla sulfadiazina (connettivina plus) nel trattamento delle lesioni da pressione: uno studio di coorte osservazionale prospettico. Professioni Infermieristiche 2009; 62:67–77

    19. Gibson D, Cullen B, Legerstee R, Harding KG, Schultz G. „MMP’s made easy“, Wounds International Volume 1 | Issue 1 | November 2009

    20. Winter, GD: Nature 1962; 193: 293-4

    21. Liguori V et al. Double-blind, randomized clinical study comparing hyaluronic acid cream to placebo in patients treated with radiotherapy. Radiother. Oncol 1997; 42:155–161 Radiother Oncol. 1997 Feb; 42(2):155–61

    22. Migliore A et al. Intra-articular injection of hyaluronic acid (MW 1,500-2,000 kDa) in symptomatic osteoarthritis oft he hip: a prospective cohort study. Arch Orthop Trauma Surg (2011) 131(12):1677-1685.

    23. Summary of Product Characteristics HyalOne®

    24. Schieb F et al. Arthritis + Rheuma 2003; 23: 338-340

    25. Foti C et al. Eur J Phys Rehabil Med 2011;47:1-9

    26. Priano F, Guelfi M. Artroscopia 2007; 8(1): 3-12

    27. Finelli I et al. Biorheology, 2011; 48(5):263

    28. Finelli I et al. Macromol Biosci 2009; 9: 646-653

    29. Fidia; Data on file

    30. Goldberg VM et al.: Osteoarthritis Cartilage, 13: 216–224; 2005

    31. Pavelka K et al. Acta Chir Orthop Traumatol Cech. 1995; 62 (6): 362–366.

Fidia weltweit

Entdecken Sie auch die internationalen Webseiten von Fidia:

Fidia Farmaceutici s.p.a.
Fidia Pharma USA Inc
Fidia Farmaceutica S.L.U.

Fidia Pharma GmbH

Die Stärke aus über 50 Jahren Erfahrung, Forschung, Entwicklung & Vermarktung von Therapieoptionen mit Hyaluronsäure nutzend, starteten wir ab 2014 in Deutschland die Markteinführung genau dieser innovativen Therapieoptionen für die Arthrosetherapie und das moderne Wundmanagement. Weitere Bereiche werden in den kommenden Jahren folgen.